PAPER OF THE MONTH - JUNE 2020

New live-attenuated vaccine against RSV (MinL4.0) progresses to clinical development
Mueller S, Stauft CB, Kalkeri R, Koidei F, Kushnir A, Tasker S, Coleman JR.
​
A novel codon-deoptimized RSV vaccine protected African Green Monkeys against viral replication and induced neutralizing antibodies as well as cellular IFNg response against RSV. Deoptimized vaccines are generated in vitro with the aim to impair replication in human cells through multiple synonymous codon changes. The idea is that the amino acid order is not changed. The vaccine was tested in African Green Monkeys challenged with RSV A2. Replication of MinL4.0 was decreased a 100-fold compared to wild-type A2. Anecdotally, the investigators report that there was one animal with preexistent neutralizing antibodies who still responded to MinL4.0 suggesting the vaccine can be used in exposed individuals. The vaccine has been developed by Codagenix Inc with support of NIAID. The vaccine will now be tested as a mucosal vaccine in humans.

Out now: RESVINET T-SHIRTs

Order a ReSViNET T-Shirt and
​contribute to our research.
On 12- 14 November 2019 ReSViNET Foundation heldt its 5th conference: “RSVVW 2019 - A Global Conference on Novel RSV Preventive and Therapeutic Interventions" in Accra, Ghana. ​We look back on a successful, exciting and inspiring meeting. Our special thanks to our sponsors to make this event possible and our chairs and scientific advisory board. Last but not least we thank all the speakers and participants for their contributions. ​

Recent developments in RSV Interventions

Interested in the recent developments of RSV? Then watch the REPLAY here. Prof. Louis Bont and Dr. Natalie mazur will give a full summary of the highlights of the #RSVVW19 conference in Accra.
​ 

AWARENESS OF RSV AS A GLOBAL HEALTH PROBLEM IS LACKING

To raise and spread awareness, we have launched a ‘RSV Mortality Awareness’ campaign at the start of the RSVVW2019 conference on November 12, by sharing a personal video entitled “Why we should all know about RSV” about Simone van Wyck, a mother who lost her son due to RSV. The RSV awareness video was produced in collaboration with the Bill & Melinda Gates Foundation.

ABOUT RESVINET FOUNDATION

RSV (Respiratory Syncytial Virus) infection is the second most important cause of death during infancy, especially in developing countries. 
Since the inception of ReSViNET network in 2014, we have continuously been working to fulfil our Vision and Mission with the goal to decrease the global burden of RSV infection through the advancement of research; providing scientific input and involvement in clinical trials. ReSViNET Foundation is a financially and otherwise independent regulated entity.
ReSViNET Foundation is certified by NGOsource as equivalent to a U.S. public charity!
We would like to express our sincere condolences to Neeltjes' family for their loss. Jan. 2020.
Neeltje from The Netherlands, 99 years old, participant of the RESCEU Older adults study. RSV is an important cause of pneumonia in older adults. Awareness of RSV in older adults is almost absent. Every year about 3-6% of all older adults are infected with RSV. Course of disease is most severe on older adults with severe underlying disease such as heart failure or COPD.
​

Educational activities

PeerVoice has launched three RSV activities, in collaboration with and endorsed by ReSViNET Foundation. Use the link below for more information and content of the programs.

ReSViNET Global partners